Individual 5-fluorouracile dose optimization in folfiri treatment
US9463193B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Sep 26, 2008 |
| Grant date | Oct 11, 2016 |
| Priority date | — |
| Expiry date | Nov 8, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P39/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention belongs to the field of improved personalized medicine. More precisely, the present invention relates to a method for progressively optimizing the 5-FU dose administered by continuous infusion in patients treated by a FOLFIRI regimen or a similar regimen, based on the 5-FU plasmatic concentration measured during the previous 5-FU continuous infusion and on a herein described decision algorithm. The present invention also relates to a method for treating a cancer patient in which the 5-FU dose administered in continuous infusion in each FOLFIRI or similar treatment cycle is optimized using the decision algorithm according to the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.